<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: An increased risk of therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) after high-dose therapy and autologous stem-cell transplantation (ASCT) for malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has been described by several studies, reporting a highly variable incidence ranging from 1% to 12% </plain></SENT>
<SENT sid="1" pm="."><plain>To assess this risk more precisely, the German Low Grade <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Study Group investigated the incidence of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after ASCT on the basis of a randomized comparison of ASCT versus interferon alfa (IFN-alpha) maintenance in indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Between 1996 and 2002, 440 patients with indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were randomly assigned after a <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi>-like induction therapy regimen to myeloablative radiochemotherapy followed by ASCT or IFN-alpha </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of secondary <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> was determined by standardized follow-up of <z:hpo ids='HP_0000001'>all</z:hpo> study patients </plain></SENT>
<SENT sid="4" pm="."><plain>Bone marrow samples from patients with proven or suspected t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were centrally reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After a median follow-up of 44 months, 431 patients were assessable </plain></SENT>
<SENT sid="6" pm="."><plain>Five of 195 patients developed a secondary <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> after ASCT </plain></SENT>
<SENT sid="7" pm="."><plain>Two of these patients developed a <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Accordingly, the estimated 5-year risk for secondary hematologic <z:hpo ids='HP_0002664'>neoplasias</z:hpo> after ASCT was 3.8% </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, in the IFN-alpha arm, the 5-year risk of hematologic <z:hpo ids='HP_0002664'>neoplasias</z:hpo> was 0.0% (P = .0248) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The data of this randomized trial demonstrate an increased risk of secondary <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> after myeloablative radiochemotherapy and ASCT compared with conventional chemotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>However, as ASCT significantly improves progression-free survival, it is currently not evident to what extent the higher rate of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> will diminish the benefit of ASCT in indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>